What biomarker tests are recommended for Prostate Cancer

Biomarker Tests for Prostate Cancer

Based on current medical guidelines, biomarker testing plays an important role in prostate cancer care—but the specific tests recommended depend on your cancer stage and risk level. Let me walk you through what's available and how doctors use them.

Standard Initial Tests

According to the NCCN Guidelines, when you're first evaluated for prostate cancer, your care team will typically start with:

PSA (Prostate-Specific Antigen) Blood Test

• This measures a protein your prostate produces
• Elevated PSA can suggest cancer, but it's not specific to cancer alone
• Used to monitor disease over time

Digital Rectal Exam (DRE)

• Your doctor physically examines the prostate to feel for lumps or abnormalities

Blood and Urine Biomarker Tests (Early Detection/Risk Assessment)

If your PSA is elevated, the NCCN Guidelines recommend additional blood and urine tests to help decide if further testing is needed:

Blood Tests:

• 4Kscore - measures PSA and other proteins
• PHI (Prostate Health Index) - combines PSA measurements
• IsoPSA - measures different forms of PSA

Urine Tests:

• ExoDx - analyzes genetic material in urine
• PCA3 - detects cancer-related RNA in urine
• SelectMDx - genetic test from urine samples
• MPS (Michigan Prostate Score) - combines multiple markers

Advanced Molecular Biomarker Tests (For Risk Stratification)

According to the NCCN Guidelines, if you have early-stage prostate cancer, your doctor may recommend molecular biomarker tests to better predict your cancer's behavior. These tests are particularly valuable because they can help identify patients with lower-risk cancer who may not need aggressive treatment right away.

Common Gene Expression Tests:

• Decipher (22-gene genomic classifier) - predicts risk of distant metastasis (cancer spread)
• Genomic Prostate Score (GPS) - 17-gene assay measuring cancer aggressiveness
• Prolaris (31-gene assay) - measures cancer cell growth rate

Important Note: According to the NCCN Guidelines, these advanced tools are not recommended for patients with very-low-risk prostate cancer and should only be ordered when they have the potential to change your treatment plan.

Genetic Testing (Germline Testing)

The NCCN Guidelines recommend germline (inherited) genetic testing if you have:

• A family history of cancer
• Early-onset prostate cancer
• Specific cancer patterns in your family

This testing looks for inherited mutations in genes like BRCA1, BRCA2, HOXB13, ATM, and PALB2 that increase cancer risk and may influence treatment options.

For Advanced/Metastatic Prostate Cancer

If your cancer has spread, the NCCN Guidelines recommend somatic tumor testing (analyzing cancer cells, not normal cells) to look for:

DNA Repair Gene Mutations:

• BRCA1/BRCA2, ATM, PALB2, CHEK2, CDK12 - mutations in these genes may respond to PARP inhibitors (drugs that block DNA repair)

Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR):

• These indicate your cancer cells have difficulty correcting DNA errors
• May respond to immunotherapy drugs like pembrolizumab

Tumor Mutational Burden (TMB):

• Measures the total number of mutations in your cancer
• High TMB may indicate immunotherapy responsiveness

PSMA-PET Imaging:

• Uses a radioactive tracer to locate prostate cancer cells throughout your body
• Helps determine if cancer has spread

How Doctors Decide Which Tests to Order

According to NCCN Guidelines, molecular biomarker tests should only be ordered when they have the potential to change your treatment decisions. Your doctor will consider:

• Your cancer stage and risk group
• Your PSA level and Gleason score (how aggressive the cancer looks under a microscope)
• Whether you're considering active surveillance, surgery, radiation, or other treatments
• Your overall health and life expectancy

Questions to Ask Your Healthcare Team

1. Based on my cancer stage and risk level, which biomarker tests do you recommend for me?
2. How will these test results change my treatment options?
3. If I have molecular testing done, what specific genes or markers will be analyzed?
4. Do I need germline (inherited) genetic testing, and if so, should I see a genetic counselor?
5. How often will my biomarkers be monitored during and after treatment?
6. Are there clinical trials available that use biomarker testing to guide treatment?

Key Takeaway

Biomarker testing is increasingly important in prostate cancer care because it helps personalize your treatment plan. However, not every patient needs every test. The right tests for you depend on your specific situation—your cancer stage, risk level, and what treatment decisions you're facing.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.